Affimed

Affimed EV/OCF

Delisted

The EV/OCF (Enterprise Value to Operating Cash Flow) of Affimed (AFMD) as of Nov 16, 2026 is 0.48. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 1.63 — a change of -70.64% (lower).

EV/OCF

0.48

YoY

-70.64%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Affimed is 2023 0.48 . EV/OCF (Enterprise Value to Operating Cash Flow) of Affimed was 2022 1.63 . It decreases by -70.64% lower compared to the previous year.

The Affimed EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2016
1.23 EUR
Jan 1, 2017
1.25 EUR
Jan 1, 2018
-2.09 EUR
Jan 1, 2019
3.45 EUR
Jan 1, 2020
7.47 EUR
Jan 1, 2021
2.06 EUR
Jan 1, 2022
1.63 EUR
Jan 1, 2023
0.48 EUR
The Affimed EV/OCF history
YEAREV/OCFYoY
0.48-70.64%
1.63-20.62%
2.06-72.44%
7.47+116.37%
3.45-265.08%
-2.09-266.80%
1.25+1.54%
1.23-68.00%
3.86+15.64%
3.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Affimed Stock analysis

What does Affimed do? Affimed NV develops targeted cancer immunotherapies focused on immuno-oncology, leveraging the immune system to combat tumor cells. The company's product pipeline includes AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma, AFM13 combined with adoptive NK cells or anti-PD-1, and AFM24 for advanced EGFR-expressing solid tumors. Affimed is conducting a registration-directed study for AFM13 and a Phase 1/2a study for AFM24, alongside preclinical candidates like AMF26 for multiple myeloma and AMF28/AMF32 for multiple tumor targets. The firm collaborates with Genentech to develop and commercialize certain product candidates for multiple cancers. Affimed generates revenue primarily through collaboration agreements, such as the partnership with Genentech, which covers development and commercialization of specific therapies. The company's primary customers are pharmaceutical and biotechnology firms seeking to expand their oncology portfolios, particularly those interested in immuno-oncology approaches. Affimed's target segments include patients with relapsed/refractory peripheral T-cell Lymphoma, advanced EGFR-expressing solid tumors, and multiple myeloma, as well as broader oncology markets for its preclinical candidates. The company's revenue streams are tied to milestone payments and potential royalties from partnered products, with Genentech being a key collaborator. Affimed's focus on immuno-oncology positions it to attract partnerships with major pharmaceutical players looking to enhance their cancer therapy offerings. Its clinical-stage products, such as AFM13 and AFM24, are in advanced development phases, making them attractive for strategic alliances that drive commercialization and revenue generation. Affimed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Affimed stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Affimed is 0.48 in 2023.

EV/OCF (Enterprise Value to Operating Cash Flow) of Affimed changed from 1.63 to 0.48, representing a -70.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Affimed since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Affimed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Affimed

All Key Metrics — Affimed